8-K: Protagonist Reports Q3 2025 Results, Advances Key Programs

Protagonist Therapeutics reported its third quarter 2025 financial results, highlighting significant progress in its icotrokinra and rusfertide programs, alongside pipeline expansion.

Summary

• New Drug Application (NDA) for icotrokinra submitted to the U.S. FDA in July 2025 for the treatment of adults and adolescents with moderate to severe plaque psoriasis.
• European Medicines Agency (EMA) application for icotrokinra submitted in September 2025.
• Rusfertide was granted Breakthrough Therapy Designation by the U.S. FDA in August 2025 for the treatment of erythrocytosis in patients with Polycythemia Vera (PV).
• Rusfertide 52-week results from the VERIFY Phase 3 Study are scheduled for presentation at the 67th Annual American Society of Hematology (ASH) meeting in December 2025.
• The U.S. NDA filing for rusfertide for the treatment of patients with PV by partner Takeda Pharmaceuticals is expected by year-end 2025.
• The first patient has been dosed in the Phase 1 trial of PN-881, a first-in-class oral IL-17 peptide antagonist.
• IND-enabling studies are progressing as planned for the triple-GLP/GIP/GCG agonists PN-477sc and PN-477o.
• An oral hepcidin development candidate is expected to be nominated by year-end 2025.
• Cash, cash equivalents, and marketable securities totaled $678.8 million as of September 30, 2025, providing an anticipated cash runway through at least the end of 2028.
• Net loss for the third quarter ended September 30, 2025, was $39.3 million, or $(0.62) per basic and diluted share, compared to a net loss of $33.2 million, or $(0.54) per basic and diluted share, for the same period in 2024.
• Net loss for the nine months ended September 30, 2025, was $85.8 million, or $(1.35) per basic and diluted share, compared to net income of $143.5 million, or $2.34 per basic share and $2.22 per diluted share, for the same period in 2024.
• License and collaboration revenue was $4.7 million for the three months ended September 30, 2025, and $38.6 million for the nine months ended September 30, 2025.
• Research and development expenses increased by $4.0 million for the three months and $9.7 million for the nine months ended September 30, 2025, primarily due to increases in drug discovery and pre-clinical research expenses.
• General and administrative expenses increased by $1.0 million for the three months ended September 30, 2025, primarily due to increases in professional services.

Sentiment

Score: 7

Explanation: While the company reported increased net losses, this is largely due to the absence of a significant one-time revenue event from the prior year, and increased R&D investment in a growing pipeline. The substantial progress in late-stage programs (icotrokinra, rusfertide) with regulatory submissions and Breakthrough Therapy Designation, coupled with a strong cash position and extended runway, indicates robust operational execution and significant future potential. The expansion of partnered programs and initiation of new wholly-owned trials are strong positive indicators for long-term growth.

Positives

• NDA and EMA submissions for icotrokinra for moderate to severe plaque psoriasis have been completed, positioning the drug for potential approval and commercialization in 2026.
• Rusfertide received Breakthrough Therapy Designation from the FDA for PV, which may expedite its development and regulatory review process.
• The rusfertide NDA filing is expected by year-end 2025, also moving towards potential approval and commercialization in 2026.
• Partner Johnson & Johnson is expanding the ICONIC program for icotrokinra into additional IL-23 pathway indications, including psoriatic arthritis, ulcerative colitis, and Crohn's disease, indicating broad potential.
• The first patient has been dosed in the Phase 1 trial of PN-881, a new wholly-owned oral IL-17 peptide antagonist, expanding the company's pipeline.
• IND-enabling studies are progressing for PN-477sc and PN-477o, with clinical study initiations anticipated by mid-2026 and the second half of 2026, respectively.
• The company maintains a strong cash position with $678.8 million in cash, cash equivalents, and marketable securities as of September 30, 2025.
• The anticipated cash runway extends through at least the end of 2028, providing financial stability for ongoing development.
• Icotrokinra demonstrated clinically meaningful outcomes in the Phase 2b ANTHEM-UC study, with 31.7% of patients achieving clinical remission and 38.1% showing endoscopic improvement at Week 28.
• Long-term 52-week data from the Phase 3 ICONIC-TOTAL study showed icotrokinra achieved high and durable rates of site-specific psoriasis clearance.
• New data from the Phase 3 ICONIC-ADVANCE 1 and 2 studies demonstrated icotrokinra's superiority compared to deucravacitinib in patients with moderate-to-severe plaque psoriasis.

Negatives

• Net loss for Q3 2025 increased to $39.3 million from $33.2 million in Q3 2024.
• Net loss for the nine months ended September 30, 2025, was $85.8 million, a significant shift from net income of $143.5 million for the same period in 2024, primarily due to a large one-time revenue recognition in 2024 from the Takeda collaboration.
• Research and development expenses increased by $4.0 million for Q3 2025 and $9.7 million for the nine months ended September 30, 2025, indicating higher operational costs.
• General and administrative expenses increased by $1.0 million for Q3 2025, primarily due to professional services.

Risks

• Ability to develop and commercialize product candidates.
• Ability to earn milestone payments under collaboration agreements with Janssen and Takeda.
• Ability to use and expand programs to build a pipeline of product candidates.
• Ability to obtain and maintain regulatory approval of product candidates.
• Ability to operate in a competitive industry and compete successfully against competitors that have greater resources.
• Ability to obtain and adequately protect intellectual property rights for product candidates.
• Actual results of operations, financial condition, and liquidity, and the development of the industry may differ materially from forward-looking statements.

Future Outlook

Icotrokinra and rusfertide are moving towards potential NDA approval and commercialization in 2026. The company anticipates clinical study initiation of PN-477sc by mid-2026 and PN-477o in the second half of 2026. A development candidate from the oral hepcidin program is expected to be nominated by year-end 2025. The company's cash runway is anticipated to extend through at least the end of 2028.

Management Comments

• "2025 continues to be a highly productive year with significant accomplishments in both partnered and wholly owned programs." Dinesh V. Patel, Ph.D., President and CEO.
• "In addition to the NDA and EMA submissions for icotrokinra for psoriasis, we are pleased to see our partner Johnson and Johnson expand the ICONIC program into additional IL-23 pathway relevant and validated I&I indications, namely psoriatic arthritis, ulcerative colitis, and Crohns disease." Dinesh V. Patel, Ph.D., President and CEO.
• "We, along with our partner Takeda, eagerly await the presentation of the rusfertide 52-week VERIFY data at ASH in December and the NDA filing for rusfertide by year end." Dinesh V. Patel, Ph.D., President and CEO.
• "As icotrokinra and rusfertide move towards potential NDA approval and commercialization in 2026, we shift our attention to the next phase of assets emerging from our validated discovery and development platform." Dinesh V. Patel, Ph.D., President and CEO.
• "I am very proud of the consistent innovation and execution capabilities of the Protagonist team." Dinesh V. Patel, Ph.D., President and CEO.

Industry Context

The biopharmaceutical industry is highly competitive and capital-intensive, with significant focus on developing novel therapies for unmet medical needs. Protagonist Therapeutics is actively participating in this landscape by advancing multiple peptide-based drug candidates, particularly in immunology and hematology. The successful progression of icotrokinra (IL-23R antagonist) and rusfertide (hepcidin mimetic) through late-stage development, coupled with new pipeline entries like PN-881 (IL-17 antagonist) and PN-477 (triple GLP/GIP/GCG agonist), positions the company within key therapeutic areas. The partnerships with Johnson & Johnson and Takeda Pharmaceuticals are common strategies in the industry to share development costs, leverage larger commercial infrastructures, and mitigate risk for high-cost late-stage trials and market access. Breakthrough Therapy Designation for rusfertide highlights the FDA's recognition of its potential to address serious conditions with unmet needs, a significant regulatory advantage.

Comparison to Industry Standards

• The company's strategy of partnering with large pharmaceutical companies like Johnson & Johnson (Janssen Biotech) and Takeda Pharmaceuticals for late-stage development and commercialization aligns with common industry practices for smaller biopharmaceutical companies to de-risk and maximize the potential of their assets.
• The granting of Breakthrough Therapy Designation for rusfertide by the FDA is a strong indicator of its potential to offer a substantial improvement over existing therapies for polycythemia vera, a designation typically reserved for drugs with compelling preliminary clinical evidence addressing serious conditions. This is a significant competitive advantage in the rare disease space.
• The expansion of icotrokinra's development into additional IL-23 pathway indications (psoriatic arthritis, ulcerative colitis, Crohn's disease) by Johnson & Johnson demonstrates confidence in the drug's mechanism of action and broad market potential, mirroring strategies seen with other successful immunology drugs.
• The cash runway through at least the end of 2028 provides a strong financial position, which is above average for many clinical-stage biotechs, allowing for continued pipeline development without immediate dilution concerns.

Stakeholder Impact

• Shareholders: Potential for significant value creation if icotrokinra and rusfertide achieve regulatory approval and commercial success. Increased R&D spending indicates investment in future growth, but current losses impact EPS. Strong cash runway reduces immediate dilution risk.
• Patients: Advancement of icotrokinra offers a potential new oral treatment option for moderate to severe plaque psoriasis, ulcerative colitis, and Crohn's disease. Rusfertide's Breakthrough Therapy Designation and impending NDA filing offer hope for a new treatment for polycythemia vera.
• Employees: Continued progress in the pipeline and strong financial position suggest stability and ongoing opportunities.
• Partners (Johnson & Johnson, Takeda): Continued collaboration and progress towards commercialization strengthen their respective pipelines and market positions.

Next Steps

• Presentation of rusfertide 52-week VERIFY data at the ASH meeting in December 2025.
• NDA filing for rusfertide by Takeda Pharmaceuticals by year-end 2025.
• Nomination of a development candidate from the oral hepcidin program by year-end 2025.
• Potential NDA approval and commercialization for icotrokinra and rusfertide in 2026.
• Clinical study initiation of PN-477sc anticipated by mid-2026.
• Clinical study initiation of PN-477o anticipated in the second half of 2026.

Key Dates

Recommendation

Despite the reported net losses, which are largely a function of increased R&D investment and the absence of a prior year's one-time revenue event, Protagonist Therapeutics demonstrates strong operational execution and significant pipeline momentum. The successful NDA and EMA submissions for icotrokinra, coupled with its expansion into multiple indications by Johnson & Johnson, and the Breakthrough Therapy Designation for rusfertide with an imminent NDA filing, position the company for potential dual commercialization in 2026. The robust cash position of $678.8 million, providing a runway through at least the end of 2028, significantly de-risks the company's near-term financial outlook. The initiation of new Phase 1 trials and progression of preclinical assets further strengthens the long-term growth prospects. These factors collectively suggest a strong investment opportunity with multiple catalysts on the horizon.

Keywords

Protagonist Therapeutics, PTGX, biopharmaceutical, drug development, clinical trials, icotrokinra, rusfertide, plaque psoriasis, polycythemia vera, IL-23 receptor antagonist, hepcidin mimetic, NDA submission, EMA application, Breakthrough Therapy Designation, Phase 3, Phase 1, PN-881, PN-477, GLP/GIP/GCG agonists, oral hepcidin, financial results, Q3 2025, biotech, pharmaceuticals, rare blood disorders, autoimmune diseases